At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 163 enrolled / 163 target
Drug / intervention
TAR-200 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy
In Brief
A Phase 2 clinical trial evaluating TAR-200 and Cetrelimab for Urinary Bladder Neoplasms. Completed, enrolled 163 participants across 109 sites in 10 countries.
Signals
Enrolling slower than its timeline implies
Detailed Summary
The purpose of this study is to evaluate the anti-tumor effects of TAR-200 in combination with intravenous (IV) cetrelimab and IV cetrelimab alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder Neoplasms
CountriesBelgium, France, Germany, Israel, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJul 2022
Primary CompletionFeb 2025
Study CompletionMar 2026
TodayJul 2026
First PostedJun 9, 2021
Enrollment StartJul 7, 2022
Primary CompletionFeb 4, 2025
Study CompletionMar 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 5.1 years ago
Arms & Interventions
Cohort 1: TAR-200 + Cetrelimabexperimental
Participants will receive TAR-200 in combination with cetrelimab.
Drug: TAR-200Biological: Cetrelimab
Cohort 2: Cetrelimabexperimental
Participants will receive cetrelimab.
Biological: Cetrelimab
Interventions
TAR-200drug
TAR-200 will be administered.
Cetrelimabbiological
Cetrelimab will be administered.